{"id":54223,"date":"2026-01-15T19:47:06","date_gmt":"2026-01-15T11:47:06","guid":{"rendered":"https:\/\/flcube.com\/?p=54223"},"modified":"2026-01-15T19:47:08","modified_gmt":"2026-01-15T11:47:08","slug":"immvira-bio-files-for-hong-kong-ipo-with-phase-ii-oncolytic-immunotherapy-mvr-t3011","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=54223","title":{"rendered":"Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011"},"content":{"rendered":"\n<p><strong>Immvira Bioscience Inc.<\/strong> filed for an initial public offering on the <strong>Hong Kong Stock Exchange<\/strong> (HKEX), advancing its pipeline of <strong>oncolytic immunotherapies<\/strong> and <strong>engineered exosome therapies<\/strong>. The company\u2019s lead asset, <strong>MVR-T3011<\/strong>, a novel <strong>HSV-1 based oncolytic virus<\/strong> expressing anti-PD-1 antibody and IL-12, is in Phase II trials for <strong>full-spectrum bladder cancer<\/strong> and <strong>third-line head and neck squamous cell carcinoma (HNSCC)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-company-overview\">Company Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Immvira Bioscience Inc.<\/td><\/tr><tr><td><strong>Founded<\/strong><\/td><td>2015<\/td><\/tr><tr><td><strong>Filing Venue<\/strong><\/td><td>Hong Kong Stock Exchange (HKEX)<\/td><\/tr><tr><td><strong>Filing Date<\/strong><\/td><td>13\u202fJan\u202f2026<\/td><\/tr><tr><td><strong>Focus Areas<\/strong><\/td><td>Oncolytic immunotherapies, engineered exosome therapies<\/td><\/tr><tr><td><strong>Pipeline<\/strong><\/td><td>2 oncolytic immunotherapy products, 5 engineered exosome products<\/td><\/tr><tr><td><strong>Core Product<\/strong><\/td><td>MVR-T3011 (HSV-1 based oncolytic immunotherapy)<\/td><\/tr><tr><td><strong>Clinical Stage<\/strong><\/td><td>Phase II<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-amp-product-profile\">Technology &amp; Product Profile<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-mvr-t3011-novel-oncolytic-immunotherapy\"><strong>MVR-T3011: Novel Oncolytic Immunotherapy<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform:<\/strong> <strong>Herpes simplex virus type 1 (HSV-1)<\/strong> backbone engineered for tumor-selective replication<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Combines <strong>potent tumor lytic activity<\/strong> with <strong>local expression of anti-PD-1 antibody<\/strong> and <strong>IL-12<\/strong>, creating a <strong>dual-pronged attack<\/strong> (direct oncolysis + immune activation)<\/li>\n\n\n\n<li><strong>Delivery:<\/strong> <strong>Intratumoral injection<\/strong> for solid tumors<\/li>\n\n\n\n<li><strong>Advantages:<\/strong><\/li>\n\n\n\n<li><strong>Overcomes systemic toxicity<\/strong> of checkpoint inhibitors<\/li>\n\n\n\n<li><strong>IL-12 expression<\/strong> enhances T-cell\/NK cell infiltration<\/li>\n\n\n\n<li><strong>Anti-PD-1 expression<\/strong> maintains sustained immune pressure within tumor microenvironment<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-engineered-exosome-platform\"><strong>Engineered Exosome Platform<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline:<\/strong> 5 exosome products (indications undisclosed)<\/li>\n\n\n\n<li><strong>Potential:<\/strong> Direct commercial applications or therapeutic delivery vehicles<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development\">Clinical Development<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Setting<\/th><th>Stage<\/th><th>Status<\/th><th>Key Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Bladder Cancer (NMIBC)<\/strong><\/td><td>Second-line post-BCG<\/td><td>Phase II<\/td><td>Ongoing<\/td><td>Addresses high-risk patients with limited options<\/td><\/tr><tr><td><strong>Bladder Cancer (NMIBC)<\/strong><\/td><td>First-line<\/td><td>Phase II<\/td><td>Planned<\/td><td>Alternative to BCG in BCG-na\u00efve patients<\/td><\/tr><tr><td><strong>Bladder Cancer (MIBC)<\/strong><\/td><td>Neoadjuvant\/adjuvant<\/td><td>Phase II<\/td><td>Planned<\/td><td>Potential to reduce cystectomy rates<\/td><\/tr><tr><td><strong>HNSCC<\/strong><\/td><td>Third-line<\/td><td>Phase II<\/td><td>Ongoing<\/td><td>Novel mechanism for checkpoint-refractory patients<\/td><\/tr><tr><td><strong>Other Solid Tumors<\/strong><\/td><td>Various<\/td><td>Preclinical<\/td><td>Active<\/td><td>Platform extensibility<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Full-Spectrum Bladder Cancer Coverage:<\/strong> Only oncolytic therapy addressing <strong>entire disease continuum<\/strong> from non-muscle invasive to muscle-invasive disease<\/li>\n\n\n\n<li><strong>Phase II Design:<\/strong> Open-label, multi-cohort study (n\u202f=\u202f~150) evaluating both <strong>monotherapy<\/strong> and <strong>combination<\/strong> regimens<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Global Market (2026E)<\/th><th>Target Population<\/th><th>Competitive Landscape<\/th><\/tr><\/thead><tbody><tr><td><strong>Bladder Cancer (all stages)<\/strong><\/td><td>$5.2\u202fbillion<\/td><td>550,000 new cases\/year<\/td><td>Merck&#8217;s Keytruda (adjuvant), BCG (NMIBC), no approved oncolytics<\/td><\/tr><tr><td><strong>BCG-unresponsive NMIBC<\/strong><\/td><td>$800\u202fmillion<\/td><td>45,000 patients (US\/EU)<\/td><td>Sesen Bio&#8217;s Vicineum (FDA CRL), no standard of care<\/td><\/tr><tr><td><strong>Third-line HNSCC<\/strong><\/td><td>$1.1\u202fbillion<\/td><td>30,000 patients<\/td><td>Keytruda, Opdivo (limited efficacy)<\/td><\/tr><tr><td><strong>Oncolytic Therapy Market<\/strong><\/td><td>$650\u202fmillion<\/td><td>Multiple solid tumors<\/td><td>Amgen&#8217;s T-VEC (melanoma only)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet Need:<\/strong> <strong>BCG-unresponsive NMIBC<\/strong> represents major gap; MVR-T3011 could capture <strong>30% market share<\/strong> upon approval<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Full-spectrum bladder cancer approach enables <strong>comprehensive commercial strategy<\/strong> and <strong>higher market penetration<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-amp-strategic-positioning\">Financial &amp; Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>IPO Proceeds:<\/strong> Estimated <strong>USD 200\u2011250\u202fmillion<\/strong> (based on comparable HKEX biotech listings)<\/li>\n\n\n\n<li><strong>Use of Funds:<\/strong> 60% clinical development, 25% manufacturing scale-up, 15% platform expansion<\/li>\n\n\n\n<li><strong>Manufacturing:<\/strong> In-house GMP facility in Shenzhen (capacity for <strong>10,000 doses\/year<\/strong>)<\/li>\n\n\n\n<li><strong>Valuation:<\/strong> Pre-money estimated at <strong>$800\u2011900\u202fmillion<\/strong> , supported by <strong>Phase II data<\/strong> and <strong>dual-platform technology<\/strong><\/li>\n\n\n\n<li><strong>Intellectual Property:<\/strong> 28 patents covering HSV-1 backbone modifications, transgene expression cassettes, and exosome engineering<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding Immvira Bio\u2019s IPO timeline, clinical development plans, and market positioning. Actual results may differ due to market conditions, regulatory review timelines, and competitive dynamics in oncolytic immunotherapy.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/sehk26011401504_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of sehk26011401504_c.\"><\/object><a id=\"wp-block-file--media-f86f4ce1-7730-4778-9f02-3f7a83d45b87\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/sehk26011401504_c.pdf\">sehk26011401504_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/sehk26011401504_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-f86f4ce1-7730-4778-9f02-3f7a83d45b87\">Download<\/a><\/div>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Immvira Bioscience Inc. filed for an initial public offering on the Hong Kong Stock Exchange&#8230;<\/p>\n","protected":false},"author":1,"featured_media":54225,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,4183,72],"class_list":["post-54223","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cancer","tag-immvira-bioscience","tag-ipo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Immvira Bioscience Inc. filed for an initial public offering on the Hong Kong Stock Exchange (HKEX), advancing its pipeline of oncolytic immunotherapies and engineered exosome therapies. The company\u2019s lead asset, MVR-T3011, a novel HSV-1 based oncolytic virus expressing anti-PD-1 antibody and IL-12, is in Phase II trials for full-spectrum bladder cancer and third-line head and neck squamous cell carcinoma (HNSCC).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=54223\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011\" \/>\n<meta property=\"og:description\" content=\"Immvira Bioscience Inc. filed for an initial public offering on the Hong Kong Stock Exchange (HKEX), advancing its pipeline of oncolytic immunotherapies and engineered exosome therapies. The company\u2019s lead asset, MVR-T3011, a novel HSV-1 based oncolytic virus expressing anti-PD-1 antibody and IL-12, is in Phase II trials for full-spectrum bladder cancer and third-line head and neck squamous cell carcinoma (HNSCC).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=54223\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-15T11:47:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-15T11:47:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1505.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54223#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54223\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011\",\"datePublished\":\"2026-01-15T11:47:06+00:00\",\"dateModified\":\"2026-01-15T11:47:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54223\"},\"wordCount\":495,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54223#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1505.webp\",\"keywords\":[\"Cancer\",\"Immvira Bioscience\",\"IPO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54223#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54223\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=54223\",\"name\":\"Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54223#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54223#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1505.webp\",\"datePublished\":\"2026-01-15T11:47:06+00:00\",\"dateModified\":\"2026-01-15T11:47:08+00:00\",\"description\":\"Immvira Bioscience Inc. filed for an initial public offering on the Hong Kong Stock Exchange (HKEX), advancing its pipeline of oncolytic immunotherapies and engineered exosome therapies. The company\u2019s lead asset, MVR-T3011, a novel HSV-1 based oncolytic virus expressing anti-PD-1 antibody and IL-12, is in Phase II trials for full-spectrum bladder cancer and third-line head and neck squamous cell carcinoma (HNSCC).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54223#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54223\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54223#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1505.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1505.webp\",\"width\":1080,\"height\":608,\"caption\":\"Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54223#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011 - Insight, China&#039;s Pharmaceutical Industry","description":"Immvira Bioscience Inc. filed for an initial public offering on the Hong Kong Stock Exchange (HKEX), advancing its pipeline of oncolytic immunotherapies and engineered exosome therapies. The company\u2019s lead asset, MVR-T3011, a novel HSV-1 based oncolytic virus expressing anti-PD-1 antibody and IL-12, is in Phase II trials for full-spectrum bladder cancer and third-line head and neck squamous cell carcinoma (HNSCC).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=54223","og_locale":"en_US","og_type":"article","og_title":"Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011","og_description":"Immvira Bioscience Inc. filed for an initial public offering on the Hong Kong Stock Exchange (HKEX), advancing its pipeline of oncolytic immunotherapies and engineered exosome therapies. The company\u2019s lead asset, MVR-T3011, a novel HSV-1 based oncolytic virus expressing anti-PD-1 antibody and IL-12, is in Phase II trials for full-spectrum bladder cancer and third-line head and neck squamous cell carcinoma (HNSCC).","og_url":"https:\/\/flcube.com\/?p=54223","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-15T11:47:06+00:00","article_modified_time":"2026-01-15T11:47:08+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1505.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=54223#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=54223"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011","datePublished":"2026-01-15T11:47:06+00:00","dateModified":"2026-01-15T11:47:08+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=54223"},"wordCount":495,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=54223#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1505.webp","keywords":["Cancer","Immvira Bioscience","IPO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=54223#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=54223","url":"https:\/\/flcube.com\/?p=54223","name":"Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=54223#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=54223#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1505.webp","datePublished":"2026-01-15T11:47:06+00:00","dateModified":"2026-01-15T11:47:08+00:00","description":"Immvira Bioscience Inc. filed for an initial public offering on the Hong Kong Stock Exchange (HKEX), advancing its pipeline of oncolytic immunotherapies and engineered exosome therapies. The company\u2019s lead asset, MVR-T3011, a novel HSV-1 based oncolytic virus expressing anti-PD-1 antibody and IL-12, is in Phase II trials for full-spectrum bladder cancer and third-line head and neck squamous cell carcinoma (HNSCC).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=54223#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=54223"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=54223#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1505.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1505.webp","width":1080,"height":608,"caption":"Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=54223#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1505.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54223","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54223"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54223\/revisions"}],"predecessor-version":[{"id":54244,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54223\/revisions\/54244"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/54225"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54223"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54223"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54223"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}